As the SIA Drug Sector continues to show mixed performance, two neutral-zone stocks—Gilead Sciences (GILD) and AbbVie Inc. (ABBV)—are emerging as potential leaders. Gilead has recently climbed 10 spots in the SIA S&P 100 Index, driven by strong quarterly gains, while AbbVie’s impressive year-to-date performance reflects its resilience in a challenging market. Both stocks have demonstrated solid relative strength, positioning them as names to watch as we move into 2025.